久久久无码人妻精品无码_6080YYY午夜理论片中无码_性无码专区_无码人妻品一区二区三区精99

  Home>News Center>World
         
 

Pfizer: Celebrex raises heart attack risk
(Agencies)
Updated: 2004-12-18 14:48

A bottle of Vioxx, right, is photographed next to a bottle Pfizer's Celebrex at a pharmacy in New York Sept. 30, 2004. Pfizer Inc. said Friday, Dec. 17, 2004, it has found an increased risk of heart problems with patients taking its painkiller Celebrex, a drug that is in the same class as the Vioxx, which was pulled from the market in September because of safety concerns. (AP
A bottle of Vioxx, right, is photographed next to a bottle Pfizer's Celebrex at a pharmacy in New York Sept. 30, 2004. Pfizer Inc. said Friday, Dec. 17, 2004, it has found an increased risk of heart problems with patients taking its painkiller Celebrex, a drug that is in the same class as the Vioxx, which was pulled from the market in September because of safety concerns. [AP]
Pfizer Inc. said it found an increased risk of heart attacks and strokes for patients taking high dosages of its top-selling arthritis painkiller Celebrex, the same problem that led to the withdrawal of its one-time competitor Vioxx.

The company said it has no plans to remove Celebrex from the market, but the disclosure on Friday sent Pfizer's shares tumbling because of fears that it could cripple sales of what had been the most-prescribed drug for treating arthritis.

Acting FDA Commissioner Lester Crawford said the government is advising physicians to consider prescribing drugs other than Celebrex to their patients.

"We're leaving open all regulatory decisions as we move forward. But we do not have a decision on the fate of the product," said Crawford, during a press briefing. "We do have great concern about this product (Celebrex) and the class of products."

But doctors have already been inundated with phone calls from worried patients and say they will curtail writing prescriptions for the drug. Shares of Pfizer, a member of the Dow index and the world's largest pharmaceutical maker, plunged $3.23, or 11.15 percent, to $25.75 in late afternoon trading on the New York Stock Exchange. The decline wiped out almost $25 billion of Pfizer's market value.

The drug industry has already been under fire for numerous high profile debacles: Merck & Co.'s withdrawal of Vioxx, the failure of Chiron Corp. to deliver half the country's flu vaccines, and disclosures that drug companies had stifled negative clinical trial data from studies examining anti-depressant use in children.

Both Celebrex and Vioxx are a type of drug called cox-2 inhibitors. Vioxx was pulled from the market in September because it doubled patients' risk of heart attack and strokes.

National Institutes of Health director Dr. Elias Zerhouni said that he ordered a full review of the more than 40 agency-supported studies involving cox-2 inhibitors.

Pfizer Global Research and Development signage is seen outside an entrance to its facility January 22, 2004 in Skokie, Illinois. Three US doctors have called for physicians worldwide to stop prescribing the pain-killing drug Bextra which is made by Pfizer, whose Celebrex drug was the subject of a separate warning.(AFP
Pfizer Global Research and Development signage is seen outside an entrance to its facility January 22, 2004 in Skokie, Illinois. Three US doctors have called for physicians worldwide to stop prescribing the pain-killing drug Bextra which is made by Pfizer, whose Celebrex drug was the subject of a separate warning.[AFP]
News of the increased heart risk for patients using Celebrex came in one of two long-term cancer prevention trials.

The National Cancer Institute, which was conducting the study for Pfizer, said patients in the clinical trial taking 800 milligrams of Celebrex had a 3.4 times greater risk of cardiovascular events compared to a placebo. For patients in the trial taking 400 milligrams of Celebrex the risk was 2.5 times greater. The average duration of treatment in the trial was 33 months.

In the 2,000 patient study, 15 individuals taking 400 mgs, 20 patients taking 800 mgs and 6 patients on placebo suffered either a cardiac-related death, heart attack or stroke.

The study was intended to show whether Celebrex could prevent precancerous growths called polyps in patients that had already had at least one such growth.

A separate cancer study done by Pfizer found no increased heart risk with patients taking 400mg of Celebrex per day.

Pfizer chairman and chief executive Hank McKinnell, who takes Celebrex, told CNN's Paula Zahn that plans to continue using the drug.

Dr. Joseph Feczko, president of worldwide development for Pfizer, noted that the results in the trial finding increased risk of heart attacks were not consistent with either the other cancer prevention trial or with a "large body of data" that the company had collected.

Feczko said in an interview later in the day that sales of Celebrex will continue because "it has not shown in totality that it increases the risk of heart attacks." He said Pfizer still hadn't seen the data from the NCI study so he couldn't speculate on how the two trials could have such different outcomes. He added that the company was still planning to go ahead with a previously announced study to see if Celebrex could actually help patients at high risk of heart attacks.

Finding patients to participate in such a study will be challenge because doctors are now saying patients at high risk of heart attacks should avoid taking Celebrex.

Dr. Garret A. FitzGerald, who has been critical of cox-2 inhibitors, said he doesn't believe Pfizer should take Celebrex off market but has to work hard to find the appropriate patient population for the drug. Cox-2s were developed to be gentler on the stomach than older pain relievers called nonsteroidal anti-inflammatory drugs, such as naproxen, that are associated with gastrointestinal problems. But unlike Vioxx, Celebrex was never statistically proven to decrease the risk of ulcers. It also doesn't reduce pain better than older drugs.

"The challenge for Pfizer now is to show why this drug should be chosen," said FitzGerald, a cardiologist at the University of Pennsylvania.

FitzGerald said Pfizer's huge marketing push behind the drug accounted for its dramatic use. Last year, Pfizer spent $87.6 million to advertise Celebrex, according to TNS Media Intelligence/CMR. It recently launched a new campaign for the drug and placed full-page ads in newspapers touting Celebrex's safety in the wake of the Vioxx recall.

Those safety claims may cause problems for the Pfizer. Citing recent company statements, including a Nov. 4 press release touting the drug's safety, U.S. Rep. Joe Barton (news, bio, voting record), R-Texas, and U.S. Rep. John Dingell, D-Mich., asked Pfizer on Friday for documents regarding Celebrex and Bextra, the company's other Cox-2 inhibitor. They want to know what information Pfizer had about the NCI study when it made the safety statements.

Additionally, they want to understand how the data safety monitor board that reviewed the ongoing trial in September and October could have determined to proceed with the study only to have it stopped two months later.

Meanwhile, Consumer Group Public Citizen called on the FDA to ban both Celebrex and Bextra.

FitzGerald said he believed the news has implications for cox-2 inhibitors such as those under development at Merck and Novartis.

"I think the trial concludes the controversy about whether there is a class effect of these drugs. Now there is clear evidence of it," said FitzGerald. "You would need to believe the earth is flat if you thought this was just a coincidence."

For the first nine months of the year, worldwide sales of Celebrex more than doubled from a year earlier to $2.3 billion, accounting for 6 percent of Pfizer's total sales of $37.6 billion during that period.

Barbara Ryan, a managing director at Deutsche Bank said she expects Celebrex's sales to fall by 50 percent next year and has dropped her Pfizer 2005 earnings estimate to $2.10 a share from $2.35 a share.

"In this environment people are hysterical," said Ryan, who said all the headlines would scare people even though the drug's problem manifested itself at high doses.

Moody's Investors Service revised its outlook on Pfizer to negative from stable because it believes Celebrex use may decline as the controversy about the class increases. Moreover, it said the likelihood that the drug could be pulled from the market may have risen and Pfizer's litigation may increase.

Moody's points out that this is happening when Pfizer is facing high exposure to patent expirations, with 30 percent to 35 percent of its revenues coming off Patent through 2007. The combination means Pfizer may not be able to maintain its triple A rating, Moody's said.

Dr. Marie Griffin, an epidemiologist and drug safety expert at Vanderbilt University, said concerns may only apply to patients taking Celebrex at high doses.

She noted that the halted study was testing a 400 to 800 milligram dose. The highest recommended dose for Celebrex to treat rheumatoid patients is 400 milligrams a day while the dose for osteoarthritis patients is 200 milligrams a day.

Still, some doctors are concerned about the drug at lower doses because different patients metabolize drugs at different rates.

"You can't say as a result of this study that doses under 400 milligrams are absolutely safe," said Dr. Eric Matteson, a professor of medicine in the division of rheumatology at the Mayo Clinic in Rochester, Minn.

Matteson said his office has been besieged with calls and that he plans to review his patients' records and take some of them off the drug. Some have specifically asked to be given something else.

The withdrawal of Vioxx has been a financial and public relations disaster for Merck. Its legal liabilities are estimated at up to $18 billion, and its shares have dropped by nearly one-third since the recall announcement in late September.

Vioxx had been a blockbuster drug for Merck, its No. 2 earner with annual global sales of $2.5 billion, amounting to 11 percent of the company's $22.49 billion in revenue last year.

Earlier this month, the Food and Drug Administration said it was adding a warning to the labels of another Pfizer drug, Bextra, noting a risk of potential heart problems associated with the use of Bextra in people who have recently had heart bypass surgery. Bextra is also a cox-2 inhibitor type of drug.

Griffin and two other Vanderbilt epidemiologists also raised fresh concerns about Bextra, in a letter to be published Thursday in the New England Journal of Medicine. Doctors should not prescribe the drug "except in extraordinary circumstances," they recommend.

Last month, in testimony before Congress an FDA official said that Bextra was one of five drugs whose sales should be halted or curtailed because it is unsafe.



 
  Today's Top News     Top World News
 

China prepares to enact law against secession

 

   
 

EU hints to lift China arms ban in June

 

   
 

GM charges Chery for alleged mini car piracy

 

   
 

More cash allotted to cut poverty

 

   
 

Unemployment rate lower than expected

 

   
 

Info chief promises media better service

 

   
  Japan delays sanctioning North Korea
   
  Saddam's defense minister faces hearing
   
  Japan, US sign missile defense agreement
   
  EU requirements dismay Turkish officials
   
  AP: Yushchenko poisoned by worst dioxin
   
  Sharon offers state to Palestinians
   
 
  Go to Another Section  
 
 
  Story Tools  
   
  News Talk  
  Are the Republicans exploiting the memory of 9/11?  
Advertisement
         
久久久无码人妻精品无码_6080YYY午夜理论片中无码_性无码专区_无码人妻品一区二区三区精99

    久草免费福利在线| 日韩精品一区在线视频| xxxxxx在线观看| 欧美黄色一级片视频| 91制片厂免费观看| 日韩精品免费播放| 特级西西444| 三级在线视频观看| 欧美精品久久久久久久自慰| 夜夜夜夜夜夜操| 色综合久久久久无码专区| 一级黄色高清视频| 91麻豆天美传媒在线| 一区二区在线播放视频| 日本男女交配视频| 日日夜夜精品视频免费观看| 日本免费一级视频| 成人在线播放网址| 三年中文高清在线观看第6集| 欧美v在线观看| 日韩精品一区二区免费| 波多野结衣三级在线| 亚洲视频在线a| 精品久久一二三| 欧美三级午夜理伦三级老人| 亚洲国产精品三区| 国产淫片av片久久久久久| 黄页免费在线观看视频| 免费看污污视频| 亚洲18在线看污www麻豆| 欧美 国产 日本| 国产欧美日韩小视频| 国产高清免费在线| 加勒比av中文字幕| www.亚洲高清| 国产三级三级三级看三级| 国产中文字幕免费观看| 色欲色香天天天综合网www| 国产一级黄色录像片| 深夜做爰性大片蜜桃| 第一区免费在线观看| 亚州精品一二三区| 美女网站免费观看视频| 久草精品在线播放| 999精品网站| 国产欧美高清在线| 男人操女人免费软件| 欧美成人三级在线视频| 国产精品无码人妻一区二区在线| 大荫蒂性生交片| 国产精品自拍合集| 亚洲一区二区图片| 一区中文字幕在线观看| 国产高清免费在线| 国产手机视频在线观看| 免费极品av一视觉盛宴| 欧洲精品在线播放| 日本日本19xxxⅹhd乱影响| 精品国偷自产一区二区三区| www..com日韩| 日本成年人网址| 蜜臀视频一区二区三区| 一区二区三区 欧美| 国产在线观看中文字幕| 99热这里只有精品7| 免费极品av一视觉盛宴| 免费看国产曰批40分钟| 爱福利视频一区二区| 91人人澡人人爽人人精品| 在线视频观看一区二区| 黄色录像特级片| 欧美大片在线播放| 欧美少妇性生活视频| 超碰在线人人爱| 国产精品探花在线播放| 一二三在线视频| 国产91在线免费| 久久这里只精品| 91免费视频黄| 黄色www网站| 97超碰成人在线| 粉嫩av一区二区三区天美传媒 | 91色国产在线| 香蕉精品视频在线| 丰满少妇大力进入| 天堂av在线网站| 三年中国中文在线观看免费播放| 2019日韩中文字幕mv| 久久久精品麻豆| 国产卡一卡二在线| 日韩av三级在线| 911福利视频| 999一区二区三区| 毛片毛片毛片毛片毛片毛片毛片毛片毛片| 精品国产乱码久久久久久1区二区| 日韩欧美猛交xxxxx无码| 日av中文字幕| 在线观看三级网站| 日韩中文字幕二区| 97超碰人人爱| 37pao成人国产永久免费视频| 国产福利精品一区二区三区| a级黄色小视频| 看看黄色一级片| 日韩avxxx| 国产日韩欧美大片| 三级视频中文字幕| 可以在线看的av网站| 嫩草视频免费在线观看| 男人添女荫道口图片| www.国产福利| 日本三级免费网站| 男女h黄动漫啪啪无遮挡软件| 国产97色在线 | 日韩| 久久综合亚洲精品| 久久婷婷综合色| 国产婷婷一区二区三区| 亚洲第一精品区| 色一情一乱一伦一区二区三区日本| 亚洲激情免费视频| 污污视频网站在线| 88av.com| 国产成人在线免费看| 美国av在线播放| 亚洲一级免费在线观看| 日日鲁鲁鲁夜夜爽爽狠狠视频97 | 三上悠亚av一区二区三区| 日韩欧美亚洲天堂| 日本国产中文字幕| www.偷拍.com| 手机av在线网| 亚洲黄色av网址| 欧美不卡在线播放| 91视频成人免费| 男女污污视频网站| 久久综合伊人77777麻豆最新章节| 国产精品国产亚洲精品看不卡| 中文字幕免费高| 亚洲视频一二三四| 日韩精品一区中文字幕| 成人综合视频在线| 国产中文字幕乱人伦在线观看| 男女爱爱视频网站| 97精品国产97久久久久久粉红| 狠狠操狠狠干视频| 三级视频中文字幕| 亚洲男人天堂色| 久草在在线视频| 男人透女人免费视频| 日本黄色三级大片| 99爱视频在线| 国产精品va无码一区二区| 黄页网站在线观看视频| 女人色极品影院| 黄色一级大片免费| 久久国产精品免费观看| 肉大捧一出免费观看网站在线播放| 超碰中文字幕在线观看| 欧美日韩久久婷婷| 交换做爰国语对白| 天天综合中文字幕| 日韩一二区视频| 日韩免费在线观看av| 欧美高清中文字幕| 国产日本在线播放| 精品无码一区二区三区在线| 青青青免费在线| 无码aⅴ精品一区二区三区浪潮 | 国产精彩免费视频| 日本xxxxxxx免费视频| 精品久久久噜噜噜噜久久图片| 国内自拍视频一区| 日韩一区二区三区久久| 久久精品国产露脸对白| aaaaaaaa毛片| 国产精品igao激情视频| av在线播放亚洲| 国产日韩成人内射视频| 一个色综合久久| 丰满人妻一区二区三区53号| 我的公把我弄高潮了视频| 久久网站免费视频| 一区二区三区入口| 经典三级在线视频| 久在线观看视频| 欧美特级aaa| 黄色免费高清视频| 激情五月宗合网| 九一精品在线观看| 日韩最新中文字幕| 亚洲午夜无码av毛片久久| 污色网站在线观看| 国内外成人激情免费视频| 国产精品久久中文字幕| 91国产精品视频在线观看| 蜜臀av.com| jizzjizzxxxx| 手机av在线网站| 老太脱裤让老头玩ⅹxxxx| 波多结衣在线观看|